Ribonucleotide reductase large subunit (RRM1) as a novel therapeutic target in multiple myeloma.

Conclusions: Our results therefore demonstrate that RRM1 is a novel therapeutic target in MM in preclinical setting, and provide the basis for clinical evaluation of RRM1 inhibitor, alone or in combination with DNA damaging agents, to improve patient outcome in MM.
PMID: 28442502 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 25, 2017 Category: Cancer & Oncology Authors: Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC Tags: Clin Cancer Res Source Type: research